IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$499.30 USD
+10.06 (2.06%)
Updated Apr 26, 2024 04:00 PM ET
Pre-Market: $499.47 +0.17 (0.03%) 8:58 AM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IDXX 499.30 +10.06(2.06%)
Will IDXX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IDXX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDXX
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
IDXX: What are Zacks experts saying now?
Zacks Private Portfolio Services
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates
Other News for IDXX
Idexx Laboratories price target lowered by $5 at BofA, here's why
With rate cuts pushed out, Goldman looks at quality stocks
The spread of avian flu to cattle could have implications for some stocks
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today
Baron Focused Growth Fund Q1 2024 Shareholder Letter